- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00104676
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
PURPOSE: This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well they work in treating patients with stage II or stage III non-seminomatous germ cell tumors.
Study Overview
Status
Intervention / Treatment
Detailed Description
OBJECTIVES:
- Compare progression-free survival rates of patients with poor prognosis stage II or III non-seminomatous germ cell tumors with an unfavorable decrease of tumor markers after treatment with 1 course of bleomycin, etoposide, and cisplatin followed by subsequent treatment with 3 additional courses of bleomycin, etoposide, and cisplatin OR dose-dense sequential combination chemotherapy.
- Compare overall survival of patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study.
Patients receive 1 course of bleomycin, etoposide, and cisplatin (BEP). Patients with a favorable decrease of tumor markers after 1 course of BEP receive 3 additional courses of BEP. Patients with an unfavorable decrease of tumor markers after 1 course of BEP are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive 3 additional courses of BEP.
- Arm II: Patients receive dose-dense sequential combination chemotherapy comprising cisplatin, etoposide, bleomycin, paclitaxel, oxaliplatin, and ifosfamide.
PROJECTED ACCRUAL: A total of 260 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49100
- Centre Paul Papin
-
Bordeaux, France, 33076
- Institut Bergonié
-
Brest, France, 29609
- C.H.U. de Brest
-
Caen, France, 14076
- Centre Regional Francois Baclesse
-
Grenoble, France, 38043
- CHU de Grenoble - Hopital de la Tronche
-
Lille, France, 59020
- Centre Oscar Lambret
-
Lyon, France, 69008
- Centre Leon Berard
-
Marseille, France, 13273
- Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes
-
Metz, France, 57038
- Hopital Notre-Dame de Bon Secours
-
Montpellier, France, 34298
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
-
Nice, France, 06189
- Centre Antoine Lacassagne
-
Paris, France, 75015
- Hopital Europeen Georges Pompidou
-
Paris, France, 75970
- Hopital Tenon
-
Reims, France, 51056
- Institut Jean Godinot
-
Rennes, France, 35042
- Centre Eugene Marquis
-
Rodez, France, 12027
- Centre Hospitalier de Rodez
-
Rouen, France, 76038
- Centre Henri Becquerel
-
Saint-Herblain, France, 44805
- CRLCC Nantes - Atlantique
-
Toulouse, France, 31052
- Institut Claudius Regaud
-
Tours, France, 37044
- Centre Hospitalier Universitaire Bretonneau de Tours
-
Vandoeuvre-les-Nancy, France, 54511
- Centre Alexis Vautrin
-
Villejuif, France, F-94805
- Institut Gustave Roussy
-
-
-
-
-
Bratislava, Slovakia, 833 10
- National Cancer Institute - Bratislava
-
-
-
-
Texas
-
Houston, Texas, United States, 77030-4009
- M. D. Anderson Cancer Center at University of Texas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
DISEASE CHARACTERISTICS:
Diagnosis of non-seminomatous germ cell tumors (NSGCT) as evidenced by 1 of the following criteria:
- Histologically confirmed NSGCT
- Clinical evidence of disease AND high serum human chorionic gonadotropin (HCG) or alpha-fetoprotein (AFP) levels
- Clinical stage II-III disease (disseminated disease)
- Testicular, retroperitoneal, or mediastinal primary site
Poor prognosis disease, meeting 1 of the following criteria:
- Mediastinal primary site
- Non-pulmonary visceral metastases
One of the following lab values:
- HCG > 50,000 UI/L
- AFP > 10,000 ng/mL
- Lactate dehydrogenase > 10 times upper limit of normal (ULN)
PATIENT CHARACTERISTICS:
Age
- Over 16
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Absolute granulocyte count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
Hepatic
- Bilirubin ≤ 1.5 times ULN
Renal
- Creatinine clearance > 60 mL/min
Other
- No other prior malignancy except basal cell skin cancer
- No HIV positivity
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm I
Patients receive 4 courses of bleomycin, etoposide, and cisplatin (BEP).
|
At least one course administered
At least one course administered
At least one course administered
|
Experimental: Arm II
Patients receive 1 course of bleomycin, etoposide, and cisplatin (BEP).
Patients then receive dose-dense sequential combination chemotherapy comprising cisplatin, etoposide, bleomycin, paclitaxel, oxaliplatin, and ifosfamide.
|
At least one course administered
At least one course administered
At least one course administered
Given in a dose-dense sequential fashion
Given in a dose-dense sequential fashion
Given in a dose-dense sequential fashion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival Rate After 1 Course of Treatment
Time Frame: 3 years from randomization
|
Primary objective is to compare the progression-free survival of participants after 1 cycle of treatment, treated randomly by 3 additional cycles of BEP (Arm I) or by T-BEP-Oxaliplatin/cisplatin-ifosfamide-Bleomycin (Arm II).
The median progression-free survival rate was defined as the median percentage of participants alive without disease progression after 1 course of treatment.
|
3 years from randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: 3 years from randomization
|
To evaluated the overall survival in both groups in participants presenting fast and slow decrease in serum levels of tumor markers.
The median overall survival was defined as the median percentage of participants alive after 1 course of treatment.
|
3 years from randomization
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Karim Fizazi, MD, PhD, Gustave Roussy, Cancer Campus, Grand Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- stage II malignant testicular germ cell tumor
- stage III malignant testicular germ cell tumor
- adult teratoma
- testicular embryonal carcinoma
- testicular choriocarcinoma
- testicular yolk sac tumor
- testicular embryonal carcinoma and teratoma
- testicular embryonal carcinoma and yolk sac tumor
- testicular yolk sac tumor and teratoma
- testicular choriocarcinoma and yolk sac tumor
- testicular choriocarcinoma and embryonal carcinoma
- testicular choriocarcinoma and teratoma
- stage III extragonadal non-seminomatous germ cell tumor
- testicular immature teratoma
- testicular mature teratoma
- stage II extragonadal non-seminomatous germ cell tumor
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Urogenital Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Genital Neoplasms, Male
- Testicular Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Testicular Neoplasms
- Teratoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Etoposide
- Paclitaxel
- Oxaliplatin
- Ifosfamide
- Bleomycin
Other Study ID Numbers
- GETUG 13
- FRE-FNCLCC-GETUG-13/0206 (Other Identifier: UNICANCER)
- 2005-001072-13 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Testicular Germ Cell Tumor
-
N.N. Petrov National Medical Research Center of...RecruitingTesticular Germ Cell TumorRussian Federation
-
Royal Marsden NHS Foundation TrustUniversity College London (UCL) Cancer InstituteUnknownTesticular Germ Cell TumorUnited Kingdom
-
National Cancer Institute (NCI)TerminatedTesticular Seminoma | Recurrent Ovarian Germ Cell Tumor | Stage II Ovarian Germ Cell Tumor | Stage III Ovarian Germ Cell Tumor | Ovarian Dysgerminoma | Recurrent Malignant Testicular Germ Cell Tumor | Stage II Malignant Testicular Germ Cell Tumor | Stage III Malignant Testicular Germ Cell TumorUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedTesticular Yolk Sac Tumor | Recurrent Ovarian Germ Cell Tumor | Recurrent Childhood Malignant Germ Cell Tumor | Recurrent Malignant Testicular Germ Cell Tumor | Childhood Extracranial Germ Cell Tumor | Childhood Malignant Ovarian Germ Cell Tumor | Childhood Malignant Testicular Germ Cell Tumor | Ovarian... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Teratoma | Stage II Malignant Testicular Germ Cell Tumor | Stage III Malignant Testicular Germ Cell Tumor | Childhood Embryonal Tumor | Childhood Extracranial Germ Cell Tumor | Childhood Extragonadal Germ Cell Tumor | Childhood Malignant Ovarian Germ Cell Tumor | Childhood Malignant Testicular... and other conditionsUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
European Organisation for Research and Treatment...CompletedTesticular Germ Cell Tumor | Unspecified Adult Solid Tumor, Protocol SpecificFrance, Netherlands, Norway, Belgium, Switzerland, Austria, United Kingdom, Germany, Denmark
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest... and other collaboratorsCompletedTesticular Germ Cell Tumor | Extragonadal Germ Cell Tumor | Childhood Germ Cell TumorUnited States, Puerto Rico, Australia, Peru
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedTesticular Seminoma | Testicular Yolk Sac Tumor | Childhood Malignant Ovarian Germ Cell Tumor | Childhood Malignant Testicular Germ Cell Tumor | Ovarian Embryonal Carcinoma | Ovarian Yolk Sac Tumor | Testicular Embryonal Carcinoma | Ovarian Choriocarcinoma | Ovarian Mixed Germ Cell Tumor | Testicular Choriocarcinoma and other conditionsUnited States
-
University of Texas Southwestern Medical CenterActive, not recruitingTesticular Germ Cell Tumor | Testicular Neoplasms | Testicular Diseases | Testis Cancer | Testicular Cancer | Germ Cell Tumor | Testicular Yolk Sac Tumor | Testicular Choriocarcinoma | Germ Cell Tumor of Testis | Germ Cell Tumor, Testicular, Childhood | Germ Cell Cancer Metastatic | Germ Cell Neoplasm of Retroperitoneum and other conditionsUnited States
-
European Organisation for Research and Treatment...UnknownTesticular Germ Cell Tumor | Teratoma | Extragonadal Germ Cell TumorFrance, Netherlands, Spain, United Kingdom, Norway, Belgium, Germany, Denmark, Hungary, Slovakia, Israel, Italy, Austria, Poland
Clinical Trials on bleomycin sulfate
-
Jinnah Postgraduate Medical CentreCompletedCutaneous WartsPakistan
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)UnknownMelanoma (Skin)United States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)Completed
-
Ichor Medical Systems IncorporatedNational Cancer Institute (NCI)Withdrawn
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of California, Los Angeles; University... and other collaboratorsCompletedHuman Immunodeficiency Virus 1 Positive | AIDS-Related Kaposi SarcomaTanzania
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI); North Central Cancer Treatment GroupCompleted
-
National Institute of Allergy and Infectious Diseases...Amgen; Sequus PharmaceuticalsCompletedHIV Infections | Sarcoma, KaposiUnited States
-
Sequus PharmaceuticalsCompletedHIV Infections | Sarcoma, KaposiUnited States
-
Medical Research CouncilCompletedTesticular Germ Cell Tumor | Teratoma | Extragonadal Germ Cell TumorUnited Kingdom
-
Nexstar PharmaceuticalsCompletedHIV Infections | Sarcoma, KaposiUnited States